Browse courses by:
By: Terry Kim, MD; Francis S. Mah, MD
This educational activity is supported by an independent medical educational grant from Shire.
Upon completion of this activity, the participant should be able to:
• Discuss the prevalence of dry eye disease and the related signs and symptoms of patients
• Develop a differential diagnosis for patients with complaints of dry eye
• Propose an individualized treatment plan for patients using current U.S. Food and Drug Administration-approved therapies
• Evaluate how dry eye disease can complicate surgical outcomes and how best to manage dry eye disease in these states
• Differentiate the need for constant maintenance and ongoing ophthalmic care for the various dry eye disease treatments.
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE CE ACCREDITATION DESIGNATION STATEMENT
In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course. This course is COPE approved for 1.0 hours of CE credit for optometrists.
COPE Course ID: 57162-AS
COPE Activity ID: 115224
Terry Kim, MD
Professor of Ophthalmology
Duke University School of Medicine
Chief, Cornea and External Disease Division
Director, Refractive Surgery Service
Duke University Eye Center
Francis S. Mah, MD
Director, Cornea and External Disease
Co-Director, Refractive Surgery
Scripps Clinic
La Jolla, CA
Terry Kim, MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Acucela; Aerie Pharmaceuticals; Alcon; Allergan plc; Avedro; Avellino Labs; Baush & Lomb; Blephex; CoDa/Ocunexus Therapeutics; Kala Pharmaceuticals; Ocular Therapeutix; Omeros; Powervision; Presbyopia Therapies; Shire; Sightlife Surgical Inc.; Simple Contacts; Tear Lab; and Tear Science. Stockholder: Kala Pharmaceuticals; NovaBay Pharmaceuticals; Ocular Therapeutix; Omeros; Sightlife Surgical, Inc.; Simple Contacts; and TearScience.
Francis S. Mah, MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speaker: Alcon; Allergan plc; AMO; Baush & Lomb; and Shire. He has received Grant/Research Support: Allergan plc; and Shire.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Evolve; and Michelle Dalton, writer have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications,
and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Shire.